Aldeyra Therapeutics to Present Novel Data on a Potential Treatment for Sjogren-Larsson Syndrome at the 2015 Society for Inherited Metabolic Disorders Annual Meeting
SLS is a rare disease caused by mutations in an aldehyde-metabolizing enzyme, fatty aldehyde dehydrogenase. In SLS, aldehyde-mediated modification of lipids (fats) is thought to disrupt the dermal moisture barrier, leading to the severe ichthyosis (dry, scaly, thickened skin) that is characteristic of the disease. Aldeyra will present the objectives, methods and results of preclinical studies evaluating the efficacy of an aldehyde trapping agent, NS2, in blocking aldehyde modification of phosphatidylethanolamine (PE), a critical lipid in biological membranes and the dermal moisture barrier. The data suggest that NS2 could have significant utility in treating the dermatologic manifestations of SLS.
The poster and date of the presentation is provided below.
-
Aldehyde Trapping Agent NS2 Blocks Formation of Fatty Aldehyde Adducts with Phosphatidylethanolamine and Suggests Potential Therapeutic Approach for Sjögren-Larsson Syndrome
Poster: 79
Date:Sunday, March 29, 2015
Location:Imperial Ballroom at theGrand America Hotel ,Salt Lake City, UT
NS2 is an aldehyde-binding small molecule based on an innovative platform technology focused on trapping free aldehydes, which are toxic and pro-inflammatory mediators of numerous diseases. By decreasing aldehyde load, NS2 may mitigate aldehyde-mediated toxicity. As a product candidate, NS2 is currently being evaluated to address two underserved rare diseases, SLS and noninfectious anterior uveitis.
About
Safe Harbor Statement
This release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Aldeyra's plans for its product candidates. In some cases, you can identify forward-looking statements by terms such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "anticipate," "project," "target," "design," "estimate," "predict," "potential," "aim," "plan" or the negative of these terms, and similar expressions intended to identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Aldeyra is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results
to differ materially from those reflected in Aldeyra's forward-looking statements include, among others, the timing and success of preclinical studies and clinical trials conducted by Aldeyra and its development partners; the ability to obtain and maintain regulatory approval to conduct clinical trials and to commercialize Aldeyra's product candidates, and the labeling for any approved products; the scope, progress, expansion, and costs of developing and commercializing Aldeyra's product candidates; the size and growth of the potential markets for Aldeyra's product candidates and the ability to serve those markets; Aldeyra's expectations regarding Aldeyra's expenses and revenue, the sufficiency of Aldeyra's cash resources and needs for additional financing; Aldeyra's ability to attract or retain key personnel; and other factors that are described in the "Risk Factors" and "Management's
Discussion and Analysis of Financial Condition and Results of Operations" sections of Aldeyra's Quarterly Report on Form 10-Q for the quarter ended
In addition to the risks described above and in Aldeyra's other filings with the
CONTACT: Corporate Contact:Source:Stephen Tulipano Aldeyra Therapeutics, Inc. Tel: +1 781-761-4904 Ext. 205 stulipano@aldeyra.com Investor Contact:David Burke The Ruth Group Tel: +1 646-536-7009 dburke@theruthgroup.com
News Provided by Acquire Media